vibecotamab
Phase 1- Indications
- Acute myeloid leukemia
Company intelligence / Profile preview
Rigel Therapeutics
South San Francisco, California, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Rigel has three commercial products: TAVALISSE, REZLIDHIA, and GAVRETO. In Q4 2024, they reported total revenue of approximately $57.6 million, including TAVALISSE net product sales of $31.0 million, REZLIDHIA net product sales of $7.4 million, and GAVRETO net product sales of $8.1 million. Their R289 program was granted Orphan Drug designation by the FDA for the treatment of MDS, with a Phase 1b study continuing to enroll patients and showing promising initial safety and efficacy data.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Eli Lilly (developing RIPK1 inhibitors)
Beyond the preview
Go deeper on Rigel Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rigel Therapeutics.